Recce Pharmaceuticals Set to Launch Diabetic Wound Topical Gel in Indonesia

HEALTH - SYDNEY – Recce Pharmaceuticals (ASX: RCE), an Australian biotech firm, is preparing to launch its new product, the world's first topical gel, in the Indonesian market.

This product is specifically designed to heal wounds in patients with diabetic foot infections (DFI). Indonesia is a priority country in the commercialization plan, in line with the ongoing phase III clinical trials in the country.

According to Cherise Ang, Vice President of Corporate Affairs at Recce, who was interviewed at her office in Sydney, Australia on Thuesday (18/11), Recce recently received approval from the Indonesian Food and Drug Supervisory Agency (BPOM) to start phase III registration clinical trials of R327G in Indonesia. 

Citing BioSpace, the clinical trials are conducted in a double-blind and placebo-controlled manner. The target is about 300 patients, where 200 patients will receive the R327G gel and the other 100 will receive a placebo.

Read Also: Indonesia to Launch Crackdown On Illegal Mines in Forests

Several treatment locations in Indonesia have been activated to recruit patients. The interim analysis results from these clinical trials are expected to be conducted in the first quarter of 2026. 

Government Support

According to Cherise Ang, Vice President of Corporate Affairs at Recce, the choice of Indonesia as a clinical trial site and strategic launch is not a coincidence. She mentioned that the Indonesian government is very supportive — the Ministry of Health, BPOM, and the private sector are facilitating the clinical trial process and regulations.

Ang also emphasized local collaboration, including with PT Etana Biotechnologies and a network of private hospitals, such as Siloam Hospital, to conduct phase III clinical trials. 

According to Recce's records, the risk of amputation in diabetes patients is very high if foot ulcers are not treated in a timely manner. 

Andre Serobian, Commercial Director at Recce, added that with the early and protocol-compliant use of the R327G gel, the risk of severe infection and complications can be significantly reduced.

Recce is optimistic that, following regulatory approval, this product can be launched in Indonesia in 2026. 

Next: US Stocks Lose Ground, Gold Resumes Its Climb as Risk Appetite Sours